Today (January 10), Deyuan Pharmaceutical (832735, BJ) announced that it plans to issue no more than 8 million shares to specific objects and raise no more than 160 million yuan for capital increase and holding no less than 55% equity of Beijing Tongli Haiyuan Biotechnology Co., Ltd. (hereinafter referred to as Tongli Haiyuan).
The reporter of the daily economic news noted that as of the end of the third quarter of last year, the owner’s equity of Tongli Haiyuan was only about 2.89 million yuan, and the net profit of Tongli Haiyuan in the first three quarters of last year was about 750000 yuan.
Deyuan pharmaceutical said that tonglihaiyuan focuses on the development of upstream GMP raw materials in the field of biomedical CGT (cell and gene therapy), is committed to providing reliable products and services for life sciences, and has a complete biomedical R & D, production and sales system.
it is proposed to increase capital to obtain no less than 55% equity of Tongli Haiyuan
Last December, Deyuan pharmaceutical announced that it had signed an intentional cooperation agreement with Wang Liyan and Tongli Haiyuan, the actual controllers of Tongli Haiyuan, and planned to obtain 55% equity of Tongli Haiyuan by means of capital increase. On January 10 this year, Deyuan pharmaceutical issued the plan for issuing shares to specific objects in 2022, which plans to raise no more than 160 million yuan to increase the capital of Tongli Haiyuan, so as to obtain the above equity
Equity structure chart of Tongli Haiyuan
Photo source: screenshot of Deyuan pharmaceutical announcement
Deyuan pharmaceutical announcement shows that up to now, the actual controller of Tongli Haiyuan is Wang Liyan. After the capital increase, the current senior management and core technical personnel of tonglihaiyuan will remain unchanged and perform their existing responsibilities.
It is understood that the above capital increase funds are used for the construction of Tongli Haiyuan Jiangsu Lianyungang Port Co.Ltd(601008) production base, the upgrading of Beijing Daxing R & D center, the upgrading of marketing center and the replenishment of working capital projects
Photo source: screenshot of Deyuan pharmaceutical announcement
For the Jiangsu Lianyungang Port Co.Ltd(601008) production base project, Deyuan pharmaceutical said that Tongli Haiyuan’s existing production capacity can no longer meet the supply demand of the market and there is an urgent need for capacity expansion. The construction of the production base of the raised investment project focuses on the improvement of the production capacity of recombinant protein and culture medium.
For the upgrading project of Beijing Daxing R & D center, Deyuan pharmaceutical said that the project will purchase advanced R & D equipment, improve R & D conditions, focus on the upgrading of technical platform and supporting process development.
intends to cut into the field of biomedicine
“This transaction will help the company quickly cut into the field of biomedicine, gradually break the monopoly of foreign brands in the field of medium and high-end biological reagents, and build an industrial layout for the coordinated development of chemical drugs and biological drugs.” Deyuan pharmaceutical said in the announcement.
Deyuan pharmaceutical said that tonglihaiyuan has long focused on the development of upstream GMP core reagents in the field of cell and gene therapy (CGT) in life science, and is committed to providing reliable products and services for life science. It is a high-tech enterprise integrating scientific research, production and operation
Photo source: screenshot of Deyuan pharmaceutical announcement
It is worth noting that as of September 30 last year, the total assets of Tongli Haiyuan were about 17.44 million yuan and the owner’s equity was about 2.89 million yuan. In the first three quarters of last year, the operating revenue was about 11.17 million yuan and the net profit was about 750000 yuan.
“Although the sales of relevant products have been realized, it still does not have large-scale production capacity and management experience. On the other hand, the biomedical industry has large R & D investment, long cycle and high professional requirements, which requires continuous capital investment. As a listed company on the Beijing stock exchange, Deyuan pharmaceutical has good financing channels to ensure the continuous development of tonglihaiyuan R & D projects.” Deyuan pharmaceutical said.
Obviously, Deyuan pharmaceutical does not value the current profitability of Tongli Haiyuan. Deyuan pharmaceutical said: “Tonglihaiyuan has long been committed to the development of new products and technologies. In terms of recombinant protein expression, it has established a mature mammalian cell and prokaryotic expression technology system. Among the products sold, there are 144 kinds of mammalian cell products and 4 kinds of prokaryotic expression products. Among them, eukaryotic protein products account for more than 97%, which is in a leading position in the industry; it has established a mature foundation in the research of immunomagnetic beads Immunomagnetic bead coupling technology and testing technology, representative products such as CD3 / CD28 monoclonal antibody coupled magnetic beads, have reached the international advanced level. “
(source: Daily Economic News)
